相关实验视频
Updated: Jul 4, 2025

07:16
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
34.6K
化可触发I型干扰素依赖的抗瘤免疫,并增强免疫治疗在肺癌中的疗效
Chuanjia Gu1,2,3, Xue Wang4, Kaiyu Wang4,5
1Department of Respiratory Endoscopy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal for immunotherapy of cancer
|January 25, 2024
概括
化可增强非小细胞肺癌 (NSCLC) 的抗瘤免疫力,通过增加CD8+T细胞和重新编程免疫微环境. 结合冷和PD-1阻断,在小鼠模型和患者中都显示出协同效果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 最少侵入性的手术
背景情况:
- 结冷处理是一种针对不可手术的非小细胞肺癌 (NSCLC) 的微创治疗方法.
- 化可能会诱导abscopal免疫效应,但其对NSCLC宿主免疫反应的影响尚未完全理解.
研究的目的:
- 在NSCLC中研究冷化对局部和全身免疫效应.
- 评估结合冷和PD-1封锁的潜力,以提高免疫治疗的疗效.
主要方法:
- 在早期NSCLC患者中评估了冷的全身免疫效应.
- 利用小鼠模型来探索冷引发的抗瘤免疫力和机制.
- 在小鼠模型和不可切割的NSCLC患者中检查了冷和PD-1阻塞的协同效果.
主要成果:
- 在NSCLC患者中,冷化增加了CD8+ T细胞和益炎性细胞因子.
- 在小鼠模型中证明了abscopal瘤生长抑制.
- 透露的冷化重新编程免疫微环境,通过依赖STING的I型IFN通路增强CD8+T细胞的透和活性.
- 与单一治疗相比,组合疗法显示出优异的瘤抑制和T细胞透.
结论:
- 结冷处理在肺癌中触发了抗瘤免疫效应.
- 化可增强PD-1/PD-L1阻断在NSCLC治疗中的有效性.
相关概念视频
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

